Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis
06 January 2021
The proportion of patients infected with SARS-CoV-2 that are prescribed antibiotics is uncertain, and may contribute to patient harm and global antibiotic resistance. Our objective was to estimate the prevalence and associated factors of antibiotic use in patients with confirmed COVID-19.
Three-quarters of patients with COVID-19 receive antibiotics, prescribing is significantly higher than the estimated prevalence of bacterial co-infection. Unnecessary antibiotic use is likely high in patients with COVID-19.
Further reading: Clinical Microbiology and Infection
Author(s): Bradley J. Langford, PharmD Miranda So, PharmD Sumit Raybardhan, BScPhm MPH Valerie Leung, BScPhm MBA Jean-Paul R. Soucy, MSc Duncan Westwood, BA Nick Daneman, MD, MSc Derek R. MacFadden, MD, ScD
Effective Surveillance Healthy Animals
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
